YEAR-END REPORT 2014
The full year 2014 and the fourth quarter in brief · Net sales amounted to MSEK 30.1 (47.0), whereof the fourth quarter MSEK 8.1 (9.7) · Net loss for the group was MSEK 59.3 (22.1), whereof the fourth quarter MSEK 21.8 (3.3) · Loss per share was SEK 0.09 (0.04), whereof the fourth quarter SEK 0.03 (0.01) · Cash flow from operating activities was MSEK -46.3 (-33.4), whereof the fourth quarter MSEK -10.7 (-7.9) · Cash and cash equivalents and other short-term investments totaled MSEK 51.6 (22.8) at the end of the period · The marketing company Karo Pharma was established